IL6 and COVID-19: Importantly, recent event of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak suggests that some tsDMARDs, targeting JAK1 and bDMARDs targeting IL-1, IL-6, GM-CSF are being investigated as potential therapies for coronavirus disease 2019 (COVID-19) in order to block cytokine storm.